Bordeaux, France – January 8, 2026 – FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure1, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader.
French Version
FineHeart secures €83 million to support its growth
